Format

Send to

Choose Destination
Anticancer Res. 1996 Nov-Dec;16(6B):3415-22.

In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer.

Author information

1
Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.

Abstract

BACKGROUND:

The p53 tumor suppressor gene is altered in up to 70% of colorectal cancers.

MATERIALS AND METHODS:

We infected the colorectal cancer cell lines SW620 and KM12L4, in which p53 is mutated, with the replication-defective adenovirus Ad5/CMV/p53 to evaluate the effects of adenovirus-mediated wild-type p53 gene transfer. Gene transduction was measured by cytochemical staining of cells infected with the Ad5/CMV/beta-gal virus and expression of the wildtype p53 protein in these cells was demonstrated by immunoblotting.

RESULTS:

Significant suppression of in vitro cell proliferation and induction of apoptosis (as measured by TUNEL assay labeling) were observed following Ad5/CMV/p53 infection. More importantly, similar effects were observed in vivo in an established nude mouse subcutaneous tumor model; significant suppression of tumor growth (60%-70%) and induction of apoptosis were observed following intratumoral injections of Ad5/CMV/p53.

CONCLUSION:

This form of therapy may provide a novel approach to colorectal cancer.

PMID:
9042200
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center